Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1598093 | 1.00 | NPC1 (0.49) | NPC1RAB9AUSP30HCRTR1HCRTR2 | |
| SCHEMBL1597965 | 0.85 | HCRTR2 (0.42) | RAB9AHCRTR1HCRTR2PRMT5ALDH1A1 | |
| SCHEMBL1597961 | 0.85 | HCRTR2 (0.42) | RAB9AHCRTR1HCRTR2PRMT5ALDH1A1 | |
| SCHEMBL1598371 | 0.85 | HCRTR2 (0.45) | NPC1RAB9AHCRTR1HCRTR2PRMT5 | |
| SCHEMBL1598372 | 0.85 | HCRTR2 (0.45) | NPC1RAB9AHCRTR1HCRTR2PRMT5 | |
| SCHEMBL1598926 | 0.83 | HCRTR2 (0.44) | RAB9AHCRTR1HCRTR2PRMT5KMT2A | |
| SCHEMBL1598920 | 0.83 | HCRTR2 (0.44) | RAB9AHCRTR1HCRTR2PRMT5KMT2A | |
| SCHEMBL1597771 | 0.82 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL1597767 | 0.82 | HCRTR1 (0.47) | HCRTR1HCRTR2 | |
| SCHEMBL4257265 | 0.80 | HCRTR2 (0.55) | HCRTR1HCRTR2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919507-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2011-04-05 | — | — | US | disclosed |
| US-7741329-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2010-06-22 | — | — | US | disclosed |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.I.C. | 2009-04-09 | — | — | US | disclosed |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-29 | — | — | US | disclosed |
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. | 2009-01-08 | — | — | US | disclosed |
| US-7432270-B2 | N-aroyl cyclic amines | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-10-07 | — | — | US | disclosed |
| EP-1956020-A2 | 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-YL]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity | SMITHKLINE BEECHAM PLC (GB) | 2008-08-13 | — | — | EP | disclosed |
| EP-1385845-B1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2008-01-09 | — | — | EP | disclosed |
| US-20040143115-A1 | N-aroyl cyclic amines | SMITHKLINE BEECHAM LIMITED (GB) | 2004-07-22 | — | — | US | disclosed |
| EP-1385845-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM PLC (GB) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002090355-A1 | N-AROYL CYCLIC AMINES | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012073-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | NPC1 1392/4885RAB9A 734/4885USP30 4204/4885 |
| US-20090093478-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | NPC1 1392/4885RAB9A 734/4885USP30 4204/4885 |
| US-20090029986-A1 | N-AROYL CYCLIC AMINES | AANAT, MAOA, MAOB | NPC1 1392/4885RAB9A 734/4885USP30 4204/4885 |
| US-20040143115-A1 | N-aroyl cyclic amines | HCRTR1, HCRTR2, CNR1 | NPC1 565/4885RAB9A 3245/4885USP30 4177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.